Patients treated with upadacitinib have lower rates of lung function decline with no significant adverse events.

Emphysema subtypes, identified via CT, may be linked to cardiopulmonary subphenotypes that can help to target cardiac care in early COPD.

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...

The first of the selected abstracts came from Wolfgang Merkt, who presented an update on a patient who originally received third-generation CD19-CAR-T ...

In the early stages of the COVID-19 epidemic, it was widely considered that young, otherwise healthy people were at low risk ...

Heart MRI can be called a more feasible gold standard for detecting fibrosis (11, 26). Diffuse fibrosis changes the wave propagation and reflection properties of the myocardium. These changes can be ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...

NHS England has signed an agreement with US pharma Vertex covering all the company’s licensed cystic fibrosis medicines, and any future uses for them. The deal follows a three-year stand off ...